Today, Elevation Oncology Inc (NASDAQ: ELEV) Takes Center Stage

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Most recently, Yahoo Finance reported about the stock as it publicized that Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Stocks Info

The company is listed on the NASDAQ and operates within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $2.97 and fluctuated between $3.0300 as its day high and $2.7719 as its day low. The current market capitalization of Elevation Oncology Inc is $125.96M. A total of 0.67 million shares were traded on the day, compared to an average of 2.64M shares.

Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, ELEV has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 3 BUYs and 4 SELLs from insiders. Insiders purchased 37,688 shares during that period but sold 30,096.

It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, ELEV has a high of $5.89 and a low of $0.36.

As of this writing, ELEV has an earnings estimate of -$0.23 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of -$0.1 per share and a lower estimate of -$0.29. The company reported an EPS of -$0.37 in the last quarter, which was -15.60% lower than expectations of -$0.32.

Balance Sheet Annually/Quarterly

An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. ELEV’s latest balance sheet shows that the firm has $146.28M in Cash & Short Term Investments as of fiscal 2021. Its Book Value Per Share was $1.47, while its Total Shareholder’s Equity was $140.70M.

Analysts Opinion

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ELEV is Buy with a score of 5.00.

Most Popular

Related Posts